2024
Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations
Jayakrishnan R, Kwiatkowski D, Rose M, Nassar A. Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations. The Oncologist 2024, 29: 833-841. PMID: 38907669, PMCID: PMC11449018, DOI: 10.1093/oncolo/oyae091.Peer-Reviewed Original ResearchMutational signaturesNon-small cell lung cancerBase substitutionsNon-small lung cancerCell lung cancerLung cancerSingle base substitutionsDoublet base substitutionsResponse to personalized treatmentGenomics effortsMutational signature analysisGenesis of cancerLoss of mismatch repairResponse to therapyMutational processesDamaged DNAAPOBEC activityMismatch repairRepair mechanismsTumor evolutionEndogenous processesMutationsPersonalized treatmentCancerTobacco smokeAbstract 4311: The interplay of SYNCRIP deficiency, APOBEC activity, and extrachromosomal DNA in castration-resistant prostate cancer drug resistance
Li X, Deng S, Wang C, Wang Y, Mu P. Abstract 4311: The interplay of SYNCRIP deficiency, APOBEC activity, and extrachromosomal DNA in castration-resistant prostate cancer drug resistance. Cancer Research 2024, 84: 4311-4311. DOI: 10.1158/1538-7445.am2024-4311.Peer-Reviewed Original ResearchProstate cancer drug resistanceCancer drug resistanceDrug resistanceProstate cancerTherapy resistanceAmerican Association for Cancer Research annual meetingsResistance to androgen receptor (AR)-targeted therapiesAndrogen receptor (AR)-targeted therapiesIncreased therapy resistanceTumor mutational burdenCRPC cell linesAPOBEC activityCastration-resistant formComplexity of drug resistanceWhole-exome sequencingContribution to drug resistanceDrivers of resistanceIn vivo modelsPatient-derived samplesExtrachromosomal DNAAPOBEC-mediated mutagenesisMutational burdenDNA damageFunctional CRISPR screensTumor behavior
2022
APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma
Cannataro VL, Kudalkar S, Dasari K, Gaffney SG, Lazowski HM, Jackson LK, Yildiz I, Das RK, Rothberg BE, Anderson KS, Townsend JP. APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma. Lung Cancer 2022, 171: 34-41. PMID: 35872531, PMCID: PMC10126952, DOI: 10.1016/j.lungcan.2022.07.004.Peer-Reviewed Original ResearchConceptsCytidine deaminationMutagenic processesDefective homologous recombinationGenomic sequencesHomologous recombinationAttractive potential targetAPOBEC mutagenesisLung squamous cell carcinomaDeamination activityCancer cell growthAPOBEC proteinsAPOBEC activityCell growthCellular proliferationNFE2L2MutationsMolecular investigationsCancer effectsPotential targetMolecular variantsAPOBECSurvival of cancerSquamous cell carcinomaDeaminationVariants
2020
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
Barroso-Sousa R, Jain E, Cohen O, Kim D, Buendia-Buendia J, Winer E, Lin N, Tolaney S, Wagle N. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Annals Of Oncology 2020, 31: 387-394. PMID: 32067680, DOI: 10.1016/j.annonc.2019.11.010.Peer-Reviewed Original ResearchConceptsHigh tumor mutation burdenTumor mutation burdenPD-1 inhibitorsBreast cancerMutation burdenMedian tumor mutation burdenDifferent mutational signaturesPembrolizumab-based therapyMetastatic breast cancerSubset of patientsMut/MbMismatch repair deficiencyGenomic profilesMutational patternsAPOBEC activityGene panel sequencingMultiple tumor typesWhole-exome sequencingDe-identified dataDurable responsesMetastatic tumorsPrimary tumorTumor subtypesPatientsTumor types
2018
APOBEC as an Endogenous Mutagen in Cancers of the Head and Neck
Sasaki T, Issaeva N, Yarbrough W, Anderson K. APOBEC as an Endogenous Mutagen in Cancers of the Head and Neck. Current Cancer Research 2018, 275-292. DOI: 10.1007/978-3-319-78762-6_10.Peer-Reviewed Original ResearchDiverse physiological processesFamily of cytidineApolipoprotein B mRNA-editing enzyme catalytic polypeptideEnzyme catalytic polypeptideU conversionBioinformatics studiesEndogenous mutagensAPOBEC3 functionGenomic DNAPhysiological processesCatalytic polypeptideEditing mechanismBioinformatics dataAPOBEC activityHuman cancersTarget nucleotidesProduction of neoantigensAPOBEC3 proteinsDiverse cancersSquamous cell carcinomaHuman papillomavirus expressionTherapeutic avenuesProteinStructural evidenceDNA
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply